LivaNova
VC Fund
London, United Kingdom
LivaNova is a VC fund in London focused on Health Care and Medical Device. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.Theyare committed to improving the lives of patients and families who deal with chronic disease, and they support the healthcare professionals who dedicate their lives to helping them. LivaNova is also dedicated to the highest standards, and they operate at the topmost level of business ethics and compliance.As a strong, market-leading medical technology and solutions company, they understand the importance of bringing both clinical and economic value to their customers. LivaNova offers a diverse product portfolio with a differentiated pipeline. Their global reach is broad with a presence in more than 100 countries and approximately 4,000 employees.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries LivaNova invests in
Stages LivaNova invests in
Countries LivaNova invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 15 contacts → | |||
Round size
- Series B
- $17M–$35M
Investment Focus
Industry
- Health Care 5 (83%)
- Medical Device 5 (83%)
- Medical 2 (33%)
- Therapeutics 2 (33%)
- Neuroscience 1 (17%)
Stage
- Series B 3 (50%)
- Series A 2 (33%)
- Funding Round 1 (17%)
Country
- United States 4 (67%)
- France 2 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ahmet Tezel
Chief Innovation Officer
|
Chief Innovation Officer | Total investments: 0 | Find email | |
Alex Shvartsburg
CFO
|
CFO | Total investments: 0 | Find email | |
Bryan Olin
Senior Vice President
|
Senior Vice President | Total investments: 0 | Find email | |
Damien McDonald
CEO
|
CEO | Total investments: 0 | Find email | |
David Wise
Chief Administrative Officer
|
Chief Administrative Officer | Total investments: 0 | Find email | |
| See all 15 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cadence Neuroscience
|
Cadence Neuroscience is an early-stage company developing new medical device therapies for the treatment of epilepsy, central pain, and other neurological disorders. The company's core technology has been developed at Mayo Clinic and is under clinical evaluation. Its medical device therapies provide medical practitioners with the procedurethat can be used to tailor brain stimulation therapy to each individual and enhance seizure control compared to currently used protocols.Cadence Neuroscience was established in 2017 and is headquartered in Redmond, Washington. | $26M / Series B / Feb 28, 2023 | |
Noctrix Health
|
Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness. | $17M / Series B / Jan 11, 2021 | |
ShiraTronics
|
ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device acceleratorcompany. | $41.7M / Series A / Oct 24, 2019 | |
Ceribell
|
Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective.The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision making. The Ceribell EEG System can be setup by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications. | $35M / Series B / Sep 25, 2018 | |
HighLife
|
HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation.The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimallyinvasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology. | $13.5M / Series A / Oct 30, 2017 | |
MD Start
|
MD Start is an incubator and fund dedicated to medical technologies. MD Start creates, develops, and operates medical projects, turning them into new companies with both strategic and hands-on approaches, in order to bring them to investment stage and commercial development. | $11.5M / Oct 14, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does LivaNova invest in?
LivaNova invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does LivaNova invest in?
LivaNova typically joins rounds of $17M–$35M at Series B. These are whole funding-round sizes, not LivaNova's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds LivaNova took part in.
How do I contact LivaNova?
Public channels for LivaNova include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at LivaNova?
The team at LivaNova includes Ahmet Tezel (Chief Innovation Officer), Alex Shvartsburg (CFO) and Bryan Olin (Senior Vice President), among 15 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
